A Phase 3 study evaluating crovalimab for participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) completed its primary endpoints on 2022-02-10. The trial reported that 78.66% of participants achieved hemolysis control. This study focused on PNH patients not previously treated with complement inhibition.
Background
The study investigated crovalimab in participants with Paroxysmal Nocturnal Hemoglobinuria (PNH). This condition was the focus for patients who had not been previously treated with complement inhibitor therapy.
Trial design
The Phase 3 study (NCT04654468) enrolled 51 participants aged 12 years or older with a body weight ≥ 40 kg, diagnosed with Paroxysmal Nocturnal Hemoglobinuria (PNH). These participants had not been previously treated with complement inhibitor therapy. The study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of crovalimab, with approximately 50 participants treated for at least 24 weeks.
Key results
The trial reported several key measurements for crovalimab:
- Mean Percentage of Participants With Hemolysis Control: 78.66 mean percentage of participants
- Difference in Percentage of Participants With Transfusion Avoidance (TA) From Baseline Through Week 25 and Within 24 Weeks Prior to Screening: 50.98 percentage of participants
- Percentage of Participants With Breakthrough Hemolysis (BTH): 3.9 percentage of participants
- Percentage of Participants With Stabilized Hemoglobin: 51.0 percentage of participants
- Change From Baseline in Fatigue in Adults Aged >=18 Years (Measurement 1): 31.77 score on a scale (Standard Deviation: 8.53)
- Change From Baseline in Fatigue in Adults Aged >=18 Years (Measurement 2): 6.67 score on a scale (Standard Deviation: 8.02)
- Change From Baseline in Fatigue in Adults Aged >=18 Years (Measurement 3): 8.08 score on a scale (Standard Deviation: 9.28)
- Change From Baseline in Fatigue in Adults Aged >=18 Years (Measurement 4): 8.15 score on a scale (Standard Deviation: 10.61)
- Change From Baseline in Fatigue in Adults Aged >=18 Years (Measurement 5): 8.77 score on a scale (Standard Deviation: 9.63)
- Percent Change From Baseline in Absolute Reticulocyte Count: 40.9411 percent change (Standard Deviation: 66.0292)
- Percent Change From Baseline in Free Hemoglobin: -45.6180 percent change (Standard Deviation: 51.8421)
- Percent Change From Baseline in Haptoglobin: 295.1351 percent change (Standard Deviation: 1735.4180)
A Paired McNemar analysis compared the percentage of participants who achieved Transfusion Avoidance (TA) from baseline through Week 25 with the percentage of participants who reported TA within 24 weeks prior to screening, yielding a p-value of 0.0001.
What this means
The primary completion of this Phase 3 study for crovalimab in Paroxysmal Nocturnal Hemoglobinuria (PNH) provides initial efficacy data for patients not previously treated with complement inhibition. The reported 78.66% hemolysis control and 50.98% transfusion avoidance suggest potential benefits for this patient population. The low percentage of breakthrough hemolysis, at 3.9%, is also a notable finding. The significant p-value of 0.0001 for transfusion avoidance comparison further supports the observed effect. These results indicate that crovalimab may offer a new treatment option for PNH patients, particularly those naive to complement inhibitors, by controlling hemolysis and reducing the need for transfusions.
Source
The information for this article was sourced from ClinicalTrials.gov, a public database of clinical studies. The primary completion date for the study NCT04654468, titled "A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition", was recorded on 2022-02-10 on clinicaltrials.gov.